VERV Verve Therapeutics, Inc.: Nilai bisnis marang pendapatan

Logo perusahaan publik Verve Therapeutics (VERV)

Verve Therapeutics (VERV) relies on a strategic alliance with a global pharma leader to fund its research. The company is implementing breakthrough gene therapy that permanently blocks high-cholesterol genes with a single injection. This chart of the company's current price-to-sales ratio reflects the market consensus, and this metric equals . The business generates revenue by creating innovative genome editing programs to combat heart attacks.

VERV Rasio nilai perusahaan marang pendapatan Verve Therapeutics (04.07.2022 - 20.11.2026)

Rincian metrik keuangan lan pasar Verve Therapeutics (VERV)

- data kapitalisasi saham perusahaan:
Pambiji fundamental:Verve Therapeutics Inc. (VERV)
Barang utama Verve

To assess the financial stability of Verve Therapeutics (VERV), I am analyzing the EV/Sales ratio, which compares the total enterprise value to annual revenue, eliminating the impact of debt load on capitalization. The trend of the EV-to-revenue ratio allows for the determination of the market's valuation of gene editing potential, where a decrease in the metric confirms the effectiveness of developing a one-time therapy for cardiac pathologies to optimize global healthcare expenditures.